Detail akcie Newron Pharma online

Business Summary: Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Newron Pharmaceuticals SpA revenues increased from EUR3.4M to EUR11.9M. Net loss decreased 99% to EUR73K. Revenues reflect Licence income from contracts with custo increase from EUR0K to EUR7.8M, Royalties from contracts with customers increase of 11% to EUR3.8M. Lower net loss reflects Research and development of pharmaceutical drugs segment income totaling EUR1.3M vs. loss of EUR7.7M.